- Home
- IONS vs CEF Comparison
IONS vs CEF Comparison
Compare IONS & CEF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- CEF
- Stock Information
- Founded
- IONS 1989
- CEF N/A
- Country
- IONS United States
- CEF
- Employees
- IONS N/A
- CEF N/A
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- CEF
- Sector
- IONS Health Care
- CEF
- Exchange
- IONS Nasdaq
- CEF NYSE
- Market Cap
- IONS 6.0B
- CEF 5.4B
- IPO Year
- IONS 1991
- CEF N/A
- Fundamental
- Price
- IONS $34.34
- CEF $23.86
- Analyst Decision
- IONS Buy
- CEF
- Analyst Count
- IONS 18
- CEF 0
- Target Price
- IONS $62.00
- CEF N/A
- AVG Volume (30 Days)
- IONS 1.1M
- CEF N/A
- Earning Date
- IONS 11-06-2024
- CEF N/A
- Dividend Yield
- IONS N/A
- CEF N/A
- EPS Growth
- IONS N/A
- CEF N/A
- EPS
- IONS N/A
- CEF N/A
- Revenue
- IONS $803,067,000.00
- CEF N/A
- Revenue This Year
- IONS N/A
- CEF N/A
- Revenue Next Year
- IONS $16.31
- CEF N/A
- P/E Ratio
- IONS N/A
- CEF N/A
- Revenue Growth
- IONS 30.57
- CEF N/A
- 52 Week Low
- IONS $34.24
- CEF N/A
- 52 Week High
- IONS $54.44
- CEF N/A
- Technical
- Relative Strength Index (RSI)
- IONS 26.91
- CEF 35.46
- Support Level
- IONS $37.18
- CEF $23.71
- Resistance Level
- IONS $40.07
- CEF $24.27
- Average True Range (ATR)
- IONS 1.38
- CEF 0.30
- MACD
- IONS -0.26
- CEF -0.26
- Stochastic Oscillator
- IONS 1.58
- CEF 5.54
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.
About CEF SPROTT PHYSICAL GOLD AND SILVER TR
Sprott Physical Gold and Silver Trust is a closed end mutual fund trust. The trust invests and holds all of its assets in physical gold and silver bullion and seeks to provide a secure, convenient, and exchange-traded investment alternative for investors interested in holding physical bullion without the inconvenience that is typical of direct investment.